Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 166 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Full Biometric Analysis

Wearable-derived biometric summary for the current observation window
Generated 2026-08-28 08:03 · Data Jan 08, 2026 to Aug 28, 2026 · Day 166 post-treatment
RMSSD
Low
21.0ms
Normal: 36-72 ms
Sleep HR
74.7bpm
Normal range
HRV Balance
Low
67/100
Oura readiness contributor
Readiness
72/100
30-day average
Sleep Score
70/100
33/224 days <60
Daily Steps
Low
3,738
90 days <2000
Vascular Age
Info
0yr
Oura estimate across 0 days
SpO2
95.7%
Lowest: 91.6%
REPORT SECTION

HRV Deep Dive

REPORT SECTION

RMSSD Comparison

REPORT SECTION

Heart Rate

REPORT SECTION

Sleep

REPORT SECTION

Readiness & Recovery

REPORT SECTION

Resilience & Vascular Age

REPORT SECTION

SpO2 & Stress

REPORT SECTION

Activity

REPORT SECTION

Clinical Summary

This summary describes the wearable signals observed in the current data window. It does not assert specific clinical history or diagnosis. Mean RMSSD is 21.0 ms, 57% below the reference median (49 ms).
RMSSD (HRV) 57% below median
21.0 ms
080 ms
Normal: 36-72 ms (P25-P75)
Sleep HR Borderline
75 bpm
40110 bpm
Normal sleep HR: 50-65 bpm
HRV Balance Critically low
67 /100
0100
Normal: 50-80 (Oura readiness component)
Daily Steps 3,738 avg
3,738 steps
010,000
Normal: 5,000-8,000 steps/day
Sleep Moderate
Score 70/100
Duration 6.6 hrs
Poor days 33/224
Sleep HRV 21 ms
Physical Capacity Severe
Activity score 62/100
Days <2k steps 90
Resilience Variable
SpO2 Low Normal
Average 95.7%
Lowest 91.6%
BOS risk Borderline
Vascular Age Estimate Estimate
Mean estimate 0 yr
Observed range 0-0 yr
Available days 0
19,373
RMSSD samples
over 231 days
57%
below reference
median
0 yr
mean vascular age
estimate
Wearable-derived snapshot for this observation window: RMSSD averages 21.0 ms, sleep heart rate is borderline, activity averages 3,738 steps/day, and the Oura vascular age estimate averages 0 yr. These are descriptive wearable outputs only, not confirmed diagnoses or verified medical history.
References (4)
  1. Kleiger RE et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62
  2. Bigger JT et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-71
  3. Shaffer F, Ginsberg JP. An Overview of HRV Metrics and Norms. Front Public Health 2017;5:258
  4. Nunan D et al. Normal values for short-term HRV. Pacing Clin Electrophysiol 2010;33:1407-17
Data window: January 08 to August 28, 2026 · Post-treatment: day 166 on ruxolitinib · Generated: 2026-08-28 08:03
Oura Ring Gen 4 consumer wearable data; N=1 exploratory case study; not a medical device. MIT License · © 2026 The Educational Equality Institute · Oura® is a registered trademark of Oura Health Oy.